**All Interactions with Delavirdine (Rescriptor)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Delavirdine** | **Effect on Drug Levels** | **Effect on Delavirdine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Alprazolam[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Xanax) | - | - | Not studied; may increase alprazolam levels | - | Increased alprazolam effects (eg, increased sedation, confusion, respiratory depression) | Inhibition of CYP450 3A4 and 2C9 by delavirdine | Avoid combination; consider alternative agents  *Alternative Agents*:  **Lorazepam** |
| Amprenavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#60)  (APV)(Agenerase) | - | - | Not studied; may increase amprenavir levels | Not studied | - | Inhibition of CYP450 3A4 by delavirdine | Dose adjustment not established |
| Amprenavir[141](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#141)  (APV)(Agenerase) | 450 mg BID x 10 days | 1000 mg BID x 10 days | Amprenavir AUC: increased 20% | Delavirdine AUC: increased 126%; Cmin: increased 372%; Cmax: increased 115%(compared to amprenavir 600 mg and delavirdine 600 mg BID) | Increased delavirdine effects | Inhibition of CYP450 3A4 by amprenavir | Dose adjustment not established |
| Amprenavir[109](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#109)  (APV)(Agenerase) | 600 mg BID | 600 mg BID | Amprenavir AUC: increased 130%; Cmax: increased 40%; Cmin: increased 125% | Delavirdine AUC: decreased 61%; Cmax: decreased 47%; Cmin: decreased 88% | Decreased delavirdine and increased amprenavir effects | Induction of CYP450 3A4 by amprenavir and inhibition of CYP450 3A4 by delavirdine | Do not coadminister |
| Amprenavir[110](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#110)  (APV)(Agenerase) | 600 mg BID | 600 mg BID | Amprenavir AUC: increased 30%; Cmax: increased 18%; Cmin: increased 90% | Delavirdine AUC: decreased 50%; Cmax: decreased 30%; Cmin: decreased 70% | Decreased delavirdine and increased amprenavir effects | Induction of CYP450 3A4 by amprenavir and inhibition of CYP450 3A4 by delavirdine | Do not coadminister |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Delavirdine** | **Effect on Drug Levels** | **Effect on Delavirdine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Antacids[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Maalox, Mylanta, Riopan, Milk of Magnesia, others) | - | 300 mg x 1 dose | Not studied | Delavirdine AUC: decreased 41% | Decreased delavirdine effects | Decreased absorption of delavirdine | Separate antacid dose by at least 1 hour before or 2 hours after delavirdine |
| Astemizole[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Hismanal) | - | - | Not studied; may increase astemizole levels | - | Increased astemizole effects (eg, cardiac arrhythmias) | Inhibition of CYP450 3A4 and 2C9 by delavirdine | Do not coadminister  *Alternative Agents*:  **Cetirizine Fexofenadine Loratadine** |
| Carbamazepine[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (others)(Tegretol) | - | - | - | Delavirdine Cmin: decreased | Decreased delavirdine effects | Induction of CYP450 3A4 by carbamazepine | Avoid combination if possible; consider alternative agents; monitor carbamazepine levels and adjust as indicated  *Alternative Agents*:  **Gabapentin Lamotrigine Tiagabine Topiramate** |
| Cimetidine[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Tagamet)(Tagamet) | - | - | - | Not studied; may decrease delavirdine absorption | Decreased delavirdine effects | Decreased absorption of delavirdine | Consider alternative agents  *Alternative Agents*:  **Famotidine Nizatidine Ranitidine** |
| Cisapride[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Propulsid) | - | - | Not studied; may increase cisapride levels | - | Increased cisapride effects (eg, cardiac arrhythmias) | Inhibition of CYP450 3A4 and 2C9 by delavirdine | Do not coadminister  *Alternative Agents*:  **Metoclopramide** |
| Clarithromycin[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Biaxin) | 500 mg BID | 300 mg TID | Clarithromycin AUC: increased 100%;14-hydroxy clarithromycin AUC: decreased 75% | Delavirdine AUC: increased 44% | Not studied | Inhibition of CYP450 3A4 and 2C9 by delavirdine | - |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Delavirdine** | **Effect on Drug Levels** | **Effect on Delavirdine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Co-trimoxazole[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (TMP/SMX, Trimethoprim/Sulfamethoxazole)(Bactrim, Septra) | - | - | - | No significant change | - | - | No dose adjustment necessary |
| Dapsone[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (others)(Avlosulfon) | - | - | Not studied; may increase dapsone levels | - | Increased dapsone effects | - | No dose adjustment necessary |
| Didanosine[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#19)  (ddI)(Videx) | - | - | Not studied | Delavirdine AUC: decreased 20% | Decreased delavirdine effects | - | Consider didanosine EC or administer delavirdine at least 1 hour prior to didanosine tablets/suspension |
| Didanosine[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#19)  (ddI)(Videx) | 125 or 200 mg (buffered formulation) Q12H | 400 mg x 1 dose | Not studied | Delavirdine AUC: decreased 32%; Cmax: decreased 53% | - | - | Dose adjustment not established |
| Didanosine[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#19)  (ddI)(Videx) | 125 or 200 mg (buffered formulation) Q12H | 400 mg x 1 dose (administered 1 hr before didanosine) | Not studied | Delavirdine AUC: increased 20%; Cmax: increased 18% | - | - | No dose adjustment necessary |
| Didanosine[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#19),[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (ddI)(Videx) | 125 or 250 mg BID x 28 days | 400 mg TID x 28 days | Didanosine AUC: decreased 21%; Cmax: decreased 20% | Delavirdine AUC: decreased 19%; Cmax: decreased 32% | - | Decreased didanosine and delavirdine absorption | Separate didanosine and delavirdine doses by at least 1 hour |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Delavirdine** | **Effect on Drug Levels** | **Effect on Delavirdine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ergotamine[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Cafergot, Ergot derivatives)(Cafergot, others) | - | - | Not studied; may increase ergotamine levels | - | Increased ergotamine effects (eg, ergotism) | Inhibition of CYP450 3A4 and 2C9 by delavirdine | Do not coadminister  *Alternative Agents*:  **5-HT agonists ("triptans")** |
| Famotidine[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Pepcid) | - | - | - | Not studied; may decrease delavirdine absorption | Decreased delavirdine effects | Decreased absorption of delavirdine | Avoid chronic coadministration  *Alternative Agents*:  **Local antacids** |
| Fluconazole[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Diflucan)(Diflucan) | 400 mg x 1 dose | 300 mg TID | No significant change | No significant change | Not studied | - | No dose adjustment necessary |
| Fluoxetine[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Prozac) | - | - | - | Delavirdine Cmin: increased 50% | Increased delavirdine effects | Inhibition of CYP450 3A4 by fluoxetine | No dose adjustment necessary |
| Indinavir[16](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#16)  (IDV)(Crixivan) | 400 mg TID x 7 days | 400 mg TID | Indinavir AUC: no signficant change; Cmax: decreased 36%; Cmin: increased 118% | No significant change | - | Inhibition of CYP450 3A4 by delavirdine | Decrease indinavir to 600 mg Q8H |
| Indinavir[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (IDV)(Crixivan) | 400 mg x 1 dose | 400 mg TID | Indinavir AUC: increased 40% | Not studied | Increased indinavir effects | Inhibition of CYP450 3A4 by delavirdine | Decrease indinavir to 600 mg Q8H |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Delavirdine** | **Effect on Drug Levels** | **Effect on Delavirdine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Indinavir[16](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#16)  (IDV)(Crixivan) | 600 mg TID x 7 days | 400 mg TID | Indinavir AUC: increased 53%; Cmax: no significant change; Cmin: increased 298% | No significant change | Increased indinavir effects | Inhibition of CYP450 3A4 by delavirdine | Decrease indinavir to 600 mg Q8H |
| Indinavir[16](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#16),[17](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#17),[18](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#18)  (IDV)(Crixivan) | 600 mg x 1 dose | 400 mg TID | Indinavir AUC: increased 44% (compared to 800 mg dose) | No significant change | Increased indinavir effects | Inhibition of CYP450 3A4 by delavirdine | Decrease indinavir to 600 mg Q8H |
| Ketoconazole[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Nizoral) | - | - | - | Delavirdine Cmin: increased 50% | Increased delavirdine effects | Inhibition of CYP450 3A4 by ketoconazole | No dose adjustment necessary |
| Lopinavir/ritonavir[78](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#78)  (LPV/r)(Kaletra) | - | - | Not studied; may increase lopinavir/ritonavir levels | - | Increased lopinavir/ritonavir effects | - | Dose adjustment not established |
| Methadone[204](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#204)  (Dolophine)(Dolophine) | 40-120 mg QD | 600 mg BID x 5 days | No significant change | No significant change | - | - | No dose adjustment necessary |
| Midazolam[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Versed) | - | - | Not studied; may increase midazolam levels | - | Increased midazolam effects (increased sedation, confusion, respiratory depression) | Inhibition of CYP450 3A4 and 2C9 by delavirdine | Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation; chronic midazolam administration (oral or intravenous) should be avoided  *Alternative Agents*:  **Lorazepam** |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Delavirdine** | **Effect on Drug Levels** | **Effect on Delavirdine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Nelfinavir[89](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#89)  (NFV)(Viracept) | 750 mg TID | 400 mg TID | Nelfinavir AUC: increased 72% | Delavirdine AUC: decreased 42%; Cmin: decreased 52% | Increased nelfinavir effects | Inhibition of CYP450 3A4 by delavirdine | Dose adjustment not established |
| Nifedipine[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Procardia, Adalat)(Adalat, Procardia) | - | - | Not studied; may increase nifedipine levels | - | Increased nifedipine effects (eg, hypotension, heart block) | Inhibition of CYP450 3A4 and 2C9 by delavirdine | Monitor and adjust nifedipine as indicated |
| Nizatidine[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Axid) | - | - | - | Not studied; may decrease delavirdine levels | Decreased delavirdine effects | Decreased absorption of delavirdine | Avoid chronic coadministration  *Alternative Agents*:  **Local antacids** |
| Phenobarbital[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (others)(Luminal) | - | - | - | Delavirdine Cmin: decreased | Decreased delavirdine effects | Induction of CYP450 3A4 by phenobarbital | Avoid combination if possible; consider alternative agents. If using, monitor and adjust phenobarbital levels as indicated.  *Alternative Agents*:  **Gabapentin Lamotrigine Tiagabine Topiramate** |
| Phenytoin[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Dilantin)(Dilantin) | - | - | - | Delavirdine Cmin: decreased | Decreased delavirdine effects | Induction of CYP450 3A4 by phenytoin | Avoid combination if possible; consider alternative agents; monitor phenytoin levels and adjust as indicated  *Alternative Agents*:  **Gabapentin Lamotrigine Tiagabine Topiramate** |
| Quinidine[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Quindex, others)(Quindex) | - | - | Not studied; may increase quinidine levels | - | Increased quinidine effects (eg, cardiac arrhythmias) | Inhibition of CYP450 3A4 and 2C9 by delavirdine | Do not coadminister |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Delavirdine** | **Effect on Drug Levels** | **Effect on Delavirdine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ranitidine[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Zantac)(Zantac) | - | - | - | Not studied; may decrease delavirdine levels | Decreased delavirdine effects | Decreased absorption of delavirdine | Avoid chronic coadministration  *Alternative Agents*:  **Local antacids** |
| Rifabutin[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Mycobutin)(Mycobutin) | 300 mg QD | 400 mg TID | Rifabutin AUC: increased 100% | Delavirdine AUC: decreased 80% | Decreased delavirdine effects; increased rifabutin effects (eg, uveitis) | Induction of CYP450 3A4 by rifabutin; inhibition of CYP450 3A4 by delavirdine | Do not coadminister |
| Rifampin[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Rifampicin)(Rifadin) | 600 mg QD | 400 mg TID | Not studied | Delavirdine AUC: decreased 96% | Decreased delavirdine effects | Induction of CYP450 3A4 by rifampin | Do not coadminister  *Alternative Agents*:  **Rifabutin** |
| Ritonavir[59](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#59)  (RTV)(Norvir) | 100 mg BID x 10 days | 600 mg BID x 10 days | Ritonavir AUC: increased 81%; Cmax: increased 50%; Cmin: increased 113% | No significant change | Increased ritonavir effects | Inhibition of CYP450 3A4 by delavirdine | No dose adjustment necessary |
| Ritonavir[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (RTV)(Norvir) | 300 mg BID | 400 or 600 mg BID | No significant change | No significant change | - | - | No dose adjustment necessary |
| Saquinavir[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (SQV)(Fortovase, Invirase) | 600 mg TID | 400 mg TID | Saquinavir AUC: increased 500% | Delavirdine AUC: decreased 15% | - | Increased saquinavir effects | - |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Delavirdine** | **Effect on Drug Levels** | **Effect on Delavirdine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Saquinavir[44](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#44)  (SQV)(Fortovase, Invirase) | 600 mg TID (hard gel caps) x 21 days | 400 mg TID x 14 days | Saquinavir AUC: increased 500% | No significant change | Increased saquinavir effects | Inhibition of CYP450 3A4 by delavirdine | Dose adjustment not established |
| Terfenadine[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Seldane)(Seldane) | - | - | Not studied; may increase terfenadine levels | - | Increased terfenadine effects (eg, cardiac arrhythmias) | Inhibition of CYP450 3A4 and 2C9 by delavirdine | Do not coadminister  *Alternative Agents*:  **Cetirizine Fexofenadine Loratadine** |
| Triazolam[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Halcion) | - | - | Not studied; may increase triazolam levels | - | Increased triazolam effects (eg, increased sedation, confusion, respiratory depression) | Inhibition of CYP450 3A4 and 2C9 by delavirdine | Do not coadminister; consider alternative agents  *Alternative Agents*:  **Lorazepam Oxazepam Temazepam Trazodone** |
| Warfarin[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (Coumadin) | - | - | Not studied | - | Increased warfarin effects (eg, increased INR, increased risk of bleeding) | Inhibition of CYP450 3A4 and 2C9 by delavirdine | Monitor INR and adjust warfarin as indicated |
| Zidovudine[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=16&post=4#88)  (AZT, ZDV)(Retrovir) | - | - | No significant change | No significant change | - | - | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 16: | Crixivan [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; Oct 2005. |
| 17: | Rescriptor [package insert]. Kalamazoo, MI: Pharmacia & Upjohn Co.; 2001. |
| 18: | Ferry JJ, Herman BD, Carel BJ, et al. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. J Acquir Immune Defic Syndr. 1998;18:252-259. |
| 19: | Videx [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2003. |
| 44: | Fortovase [package insert]. Basel, Switzerland: F. Hoffman-La Roche Ltd.;2003. |
| 59: | Tran JQ, Petersen C, Garrett M, et al. Delavirdine (DLV) significantly increases exposure of low dose ritonavir (RTV) in healthy volunteers [abstract #A-494]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois. |
| 60: | Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004. |
| 78: | Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2005. |
| 84: | Videx EC [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Oct 2005. |
| 88: | Rescriptor [package insert]. La Jolla, California: Agouron Pharmaceuticals, Inc; June 2001. |
| 89: | Cox SR, Schneck DW, Herman BD, et al. Delavirdine (DLV) and nelfinavir (NFV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers [abstract #345]. 5th Conference on Retroviruses and Opportunistic Infections. Feb 1-5, 1998. Chicago, Illinois. |
| 109: | Justesen US, Klitgaard NA, Brosen K, Pedersen C. Amprenavir is an effective inducer of delavirdine metabolism [abstract #442-W]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 February 24-28; Seattle, Washington. |
| 110: | Tran JQ, Petersen C, Garrett M, et al. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Clin Pharmacol Ther 2002;72:615-26. |
| 141: | Justesen US, Klitgaard NA, Brosen K, et al. Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. J Antimicrob Chemother 2004; May 18th |
| 204: | Booker B, Smith P, Forrest A, et al. Lack of effect of methadone (MET) on the pharmacokinetics (PK) of delavirdine (DLV) and N-delavirdine (N-DLV) [abstract #A-490]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois. |